Regulation & News
503A vs 503B Compounding Pharmacies, Explained
A plain-English guide to the two federal compounding pathways, who they cover, what quality rules apply, and why the difference matters for peptides.
What's legal. What's proven.
An independent, cited reference on longevity and peptides. Every claim links to a primary source: FDA documents, peer-reviewed research, or named news outlets. No hype, no dosing guides, no vendor links.
Start here: BPC-157 and the FDALatest regulatory updates
Regulation & News
BPC-157 and the FDA: What the July 2026 Advisory Committee Vote Actually Means
An FDA advisory panel voted 8–6 to recommend BPC-157 for the 503A bulks list. Here is what that vote did, what it did not do, and what the evidence shows.
Regulation & News
FDA's Interim Peptide Compounding Policy: What We Know So Far (Updated)
HHS and FDA sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House for review. Here is what is confirmed, what is reported, and what is still unknown.
Browse by topic
Peptide Regulatory Tracker
Status, timeline and sources for each peptide: FDA-approved, under review, compounding status, or not approved.
Regulation & News
FDA actions, compounding law (503A/503B) and advisory committees, explained with primary sources.
Evidence Reviews
What the human studies actually show. No dosing, no protocols.
Biological Age Testing
How biological-age tests work, how accurate they are, and how they compare.
Healthy Aging Basics
Sleep, exercise, protein, creatine, collagen: the evidence in plain English.